Sentences with phrase «by patient tumor»

Not exact matches

Led by Nina Bhardwaj, M.D., director of immunotherapy, the Personalized Genomic Vaccine trial uses the genetic sequence of a patient's tumor to create a customized vaccine.

The first step in the process is to surgically remove the patient's tumor and ensure that the patient is cancer free by confirming that there is no sign of cancer on blood tests and imaging studies.

Immune cells modified by CRISPR - Cas9 were inserted into a lung cancer patient at the West China Hospital in Chengdu in the hopes that they'll be able to fight tumors, and 10 people total will receive injections of CRISPR re-engineered cells in order to assess the method's safety.

For instance, most common adult solid tumors that are not cured by surgical removal are resistant to chemotherapy or radiation control, yet drug therapy is frequently offered as a «possibly effective» treatment because both patient and physician want to believe it so.

So or so, yes, not - only - external healing by faith itself of physical things (e.g., bullet in the head, tumor, spear in stomach, viri) seems, respectivly technically is, impossible, but i am pretty sure that about any patient appreciates when a surgeon is focusing at the tasks at hand particularly during operation regardless of statistics.

For example, TCGA, with genomic data on 33 tumor types taken from samples from 11,000 patients, is finishing 2018 by publishing a series of papers and holding a symposium.

Another focus in Chan's group is personalized vaccines that are based on neoantigens identified by sequencing a patient's tumor.

Overall, 34 percent of patients showed an objective response, meaning that their tumors shrank by more than 30 percent, and did not re-grow.

This suggests that in patients, drug - resistant tumor cells might be replaced by drug - sensitive tumor cells during the drug holiday.

Steven Rosenberg, chief of surgery at NCI, riveted everyone's attention by recounting the varied success of treating patients with tumor - infiltrating lymphocytes and then took a few moments to address audience members about advancing their scientific careers.

Led by Stella K. Kang, a radiologist with the Department of Radiology at the New York School of Medicine, the study was designed to compare the effectiveness of a treatment algorithm for small renal tumors incorporating the nephrometry score, a renal tumor anatomy scoring system developed by urologists, with the current standard of uniformly recommended partial nephrectomy in patients with mild - to - moderate chronic kidney disease (CKD).

They are working together to mesh her identification of compounds that target tumors with runaway Ras activity and tumor data (analyzed by machine learning) to find patients who could benefit from these potential cancer drugs.

Led by researchers at the Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James), the retrospective study suggested that a pattern of molecules called microRNA (miRNA) in tumor cells might predict patients» response to radiation therapy.

Researchers used tissue and blood samples to show that the gammopathy (a precursor to myeloma) in both mice and patients with Gaucher disease is triggered by specific lipids, and that the antibodies made by tumor cells in nearly a third of myeloma patients are directed against such lipids.

If hypofractionated radiation with curative intent can reduce the treatment time for lung cancer patients by half with no greater toxicity, and with equivalent — if not better — tumor control and survival outcomes, this research could result in a change in the paradigm of how a large subset of locally advanced NSCLC patients are treated.»

Coley was fascinated by a smattering of curious cancer stories referenced in the medical literature of the era: Patients riddled with inoperable tumors suddenly found themselves cancer - free after contracting erysipelas, another potentially fatal ailment at the time, caused by Streptococcus bacteria and marked by fever and hardened, painful rashes.

«Within the same time frame observed by Coley, our patient developed a fever, the tumor started swelling, and then it started to shrink.»

«We know that if you take these tumor cells out of a patient and put them in a petri dish, they can be killed by chemotherapy,» Beatty said.

31: The percentage of genetic mutations shared by all the tumor samples taken from a patient with kidney cancer.

Researchers at the University of Cincinnati (UC) College of Medicine have shown that a new targeted treatment could benefit patients with certain pancreatic tumors by preventing spread of the cancer and protecting their heart from damage — a direct result of the tumor.

Until recently, Ain was renowned for a highly prized repository of 18 immortal cancer cell lines, which he developed by harvesting tissue from his patients» tumors after removal, carefully culturing them to everlasting life in vials.

According to Dr. Cripe, the study suggests that some patients could respond to therapy even if their tumors aren't very infectable by the virus, provided their immune systems were stimulated by the viral therapy to attack the tumor cells.

Spearheaded by first author Christopher McNair, PhD, a graduate student in the laboratory of Dr. Knudsen, the study undertook an extensive analysis of tumor samples and cell - free DNA samples from patients with advanced, lethal - stage prostate cancer.

Preul and the team came to their results by using the confocal laser endomicroscope on 74 brain tumor patients.

«After just three treatment cycles, we saw tumor markers plummet and some patients» tumors shrink significantly in just nine weeks,» said Gayle Jameson, nurse practitioner and principal investigator of the clinical trial, who is highly encouraged by the response.

A randomized phase III trial finding that a new monoclonal antibody, elotuzumab, added to standard therapy, extended the duration of remission for patients with relapsed multiple myeloma by about five months Findings from two phase III studies showing that children with Wilms tumor who have a specific chromosomal abnormality do better with a more intensive, augmented chemotherapy regimen

The technology, developed by MIT professor and Howard Hughes Medical Institute investigator Sangeeta Bhatia, relies on nanoparticles that interact with tumor proteins called proteases, each of which can trigger release of hundreds of biomarkers that are then easily detectable in a patient's urine.

The study showed that despite the risk for receiving information about other potentially serious health problems, 59 % of the cancer patients would agree to tumor profiling if offered by their physician.

UC San Francisco researchers have found a way to knock down cancers caused by a tumor - driving protein called «myc,» paving the way for patients with myc - driven cancers to enroll in clinical trials for experimental treatments.

Among patients with non-small cell lung cancer (NSCLC) fueled by ALK gene alterations who were being treated with crizotinib (Xalkori), a decrease in the number of circulating tumor cells (CTCs) harboring increased copies of the ALK gene over the first two months of treatment was associated with increased progression - free survival.

«By understanding what causes malignant transformation we can determine what can be done for patients with benign tumors to suppress them before they reach the malignant stage,» Alman said.

Johns Hopkins researchers say they have identified a set of genes that appear to predict which tumors can evade detection by the body's immune system, a step that may enable them to eventually target only the patients most likely to respond best to a new class of treatment.

By linking these layers and others to expand from genomics to multi-omics, scientists might be able to meet the goals of personalized medicine: to figure out, for example, what treatment a particular cancer patient will best respond to, based on the network dynamics responsible for a tumor.

A team of biomedical engineers at Vanderbilt University headed by Assistant Professor Melissa Skala has developed the technique, which uses fluorescence imaging to monitor the response of three - dimensional chunks of tumors removed from patients and exposed to different anti-cancer drugs.

«Improving breast cancer chemo by testing patient's tumors in a dish.»

By examining neuroblastoma tumors biopsied from patients, the researchers demonstrate that loss of KIF1B - β is associated with poor prognosis and reduced survival.

New research led by Li Ding, Ph.D., of Washington University School of Medicine in St. Louis, shows that current approaches to genome analysis systematically miss detecting a certain type of complex mutation in cancer patients» tumors.

In Cohort A, pembrolizumab shrunk tumors by more than 30 percent in eight of 170 patients, or five percent, and stabilized the disease in 35, or 21 percent, of those previously treated for mTNBC.

By injecting T - VEC into the patients» tumors, even those that were located deeper in the body, the researchers were able to transform cold tumors into hot ones, which in turn allowed pembrolizumab to deliver a beneficial enhancement.

Glioblastoma is the most lethal form of primary brain tumor and leads to death in patients by invading the brain tissue in a process that allows single cells to move through normal brain tissue, which makes complete surgical removal of the tumor impossible.

In order to test their hypothesis in a model that more closely mimicked human disease, the researchers also tested the two drugs side - by - side on slices of tumors removed from patients during radical prostatectomy.

In Cohort B — those who received pembrolizumab as first - line therapy — 12 of 52 patients, or 23 percent, saw tumors shrink by more than 30 percent, while the disease was stabilized in nine of them, or 17 percent.

A phase I clinical trial conducted by investigators at the University of Texas San Antonio, showed that the combination of HCQ and the chemotherapy drug vorinostat in 27 patients with advanced solid tumors, including renal cell carcinoma and colon cancer, was clinically safe and inhibited autophagy.

«By accurately assessing tumor resection margins intraoperatively with CLI, surgeons may be able to completely clear the cancer with a single operation, thereby reducing the number of breast cancer patients requiring a second, or even third, surgical procedure.

«Other studies have looked at racial disparities in treatment and still others have focused on racial differences in survival rates of cancer patients, but our research attempted to go further by demonstrating the impact of race - based inequalities in cancer treatment on survival rates of black colorectal cancer patients,» said James D. Murphy, MD, MS, assistant professor and chief of the Radiation Oncology Gastrointestinal Tumor Service at UC San Diego Moores Cancer Center.

Another important aspect of the green - light KTP laser approach, Zeitels adds, is that biopsy and treatment of patients whose cancer involves a single vocal cord usually can be accomplished in the same procedure, whereas radiotherapy requires a prior biopsy to determine the extent and location of the tumor, followed by daily radiation treatments over approximately six weeks.

«By identifying this unexpected connection between DIXDC1 and LKB1 in certain tumors, we have expanded the potential patient population that may be good candidates for these therapies,» adds Goodwin.

«By helping us understand that lower levels of RNF125 confer resistance to BRAF inhibitors, we have a new strategy to stratify patients for currently approved therapy versus participation for human clinical trials to investigate whether targeting JAK1 will be more effective in patients whose tumors exhibit reduced RNF125,» said Keith T. Flaherty, M.D., associate professor, Harvard Medical School, and director of Developmental Therapeutics, Cancer Center, Massachusetts General Hospital, and co-author of the study.

The first long - term study of a pioneering endoscopic laser treatment for early vocal - cord cancer, developed at Massachusetts General Hospital (MGH) and previously shown to provide optimal voice outcomes, finds that it is as successful as traditional approaches in curing patients» tumors while avoiding the damage to vocal quality caused by radiotherapy or by conventional laser or cold - instrument surgery.

In the Scientific Reports study, researchers first performed the largest meta - analysis of the vestibular schwannoma transcriptome by studying 80 tumors from patients with sporadic and NF2 - associated vestibular schwannomas.